Barbara Mintzes

15

Articles

1

Comment
  • Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
Opioid illustration. Towfiqu barbhuiya / Pexels

Pain and the struggle for relief: How fear influences patient access to medical opioids

Elisabeth Kramer, UNSW ; Andi Hermansyah, Universitas Airlangga; Anshar Saud, Universitas Hasanuddin; Asmin Fransiska, Universitas Katolik Indonesia Atma Jaya ; Barbara Mintzes, University of Sydney; Desak Ketut Ernawati, Universitas Udayana; Kirsty Foster, The University of Queensland; Paul Glare, University of Sydney, and Simon Butt, University of Sydney

Patients in Indonesia cannot access medical opioids because the government fears drug misuse.
Ilustrasi opioid. Towfiqu barbhuiya / Pexels

Obat pereda nyeri hebat sulit didapat: Ketakutan terhadap opioid medis hambat pengobatan di Indonesia

Elisabeth Kramer, UNSW ; Andi Hermansyah, Universitas Airlangga; Anshar Saud, Universitas Hasanuddin; Asmin Fransiska, Universitas Katolik Indonesia Atma Jaya ; Barbara Mintzes, University of Sydney; Desak Ketut Ernawati, Universitas Udayana; Kirsty Foster, The University of Queensland; Paul Glare, University of Sydney, and Simon Butt, University of Sydney

Penggunaan opioid medis di Indonesia terhambat ketakutan pemerintah akan penyalahgunaan obat.
Over 90 per cent of Canadian doctors see pharmaceutical sales representatives. (Shutterstock)

Guidelines governing Canadian doctors’ relationships with pharma companies under review

Joel Lexchin, University of Toronto; Barbara Mintzes, University of Sydney; Kelly Holloway, University of Toronto, and Marc-Andre Gagnon, Carleton University

Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
Samples from volunteers are handled in the laboratory at Imperial College in London, on July 30, 2020. Imperial College is working on the development of a COVID-19 vaccine. (AP Photo/Kirsty Wigglesworth)

Canada’s COVID‑19 Vaccine Task Force needs better transparency about potential conflicts of interest

Joel Lexchin, University of Toronto; Barbara Mintzes, University of Sydney; Lisa Bero, University of Colorado Anschutz; Marc-Andre Gagnon, Carleton University, and Quinn Grundy, University of Toronto

With lives depending on a vaccine, trust in Canada’s COVID-19 Vaccine Task Force is crucial. Members of the task force need to make any industry links or potential conflicts of interest publicly clear.
The effectiveness of a drug may be evaluated based on its potential to shrink tumours – but this doesn’t necessarily equate to improved survival rates. From shutterstock.com

Do new cancer drugs work? Too often we don’t really know (and neither does your doctor)

Barbara Mintzes, University of Sydney and Agnes Vitry, University of South Australia

National drug regulators use evidence from clinical trials to decide whether new cancer drugs will be approved for use. But these studies are often flawed.

Contact Barbara for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision